Veeva SystemsBSP:V2EE34 97 Altman Z-Score is 12.14 as of Jul. 02, 2026, which is 47% below its 10-year median of 22.98. GuruFocus rates BSP:V2EE34 with a GF Score™ of 97/100 and a GF Value™ of R$47.45 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 659 Healthcare Providers & Services companies, Veeva Systems ranks better than 92.56% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 12.2 is strong.
Veeva Systems has a Altman Z-Score of 12.14, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Veeva Systems's Altman Z-Score or its related term are showing as below:
BSP:V2EE34'
s Altman Z-Score Range Over the Past 10 Years
Min: 10.71 Med: 22.98 Max: 53.66
Current: 12.2
During the past 13 years, Veeva Systems's highest Altman Z-Score was 53.66. The lowest was 10.71. And the median was 22.98.
Veeva Systems (BSP:V2EE34) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Veeva Systems Altman Z-Score Related Terms
Veeva Systems Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Veeva Systems's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:V2EE34 vs BTSG, TEM, HQY: Altman Z-Score Comparison
For the Health Information Services subindustry, Veeva Systems's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Veeva Systems's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Veeva Systems's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.6968
+
1.4
*
0.5065
+
3.3
*
0.1435
+
0.6
*
16.236
+
1.0
*
0.3837
=
12.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Veeva Systems (BSP:V2EE34) has a Altman Z-Score of 12.14 as of Jul. 02, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Veeva Systems and its competitors. This is 47% below median its historical median of 22.98. Over the past decade, Veeva Systems' Altman Z-Score has ranged from 10.71 to 53.66. According to the industry distribution chart, Veeva Systems ranks #49 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 7.4%.
Is Veeva Systems' Altman Z-Score too high?
Veeva Systems' current Altman Z-Score of 12.14 is 47% below median its 10-year median of 22.98. Over the past 10 years, this metric has ranged from a low of 10.71 to a high of 53.66. The Healthcare Providers & Services industry median Altman Z-Score is 2.41. Veeva Systems' value of 12.14 is 403.7% above this industry median. Based on the distribution chart, Veeva Systems ranks #49 out of 659 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Veeva Systems has a GF Score™ of 97/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' Altman Z-Score compare to BTSG and TEM?
According to the Healthcare Providers & Services industry distribution chart, Veeva Systems ranks #49 out of 659 companies for Altman Z-Score. This places Veeva Systems in the top 7% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.41. Veeva Systems' value of 12.14 is 403.7% above this benchmark. Historically, Veeva Systems' own Altman Z-Score has ranged from 10.71 to 53.66 over the past decade. While the company's 10-year median is 22.98 vs. the industry median of 2.41, Veeva Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.41, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current Altman Z-Score of 12.14 is 403.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current Altman Z-Score is 12.14, which is 47% below median its own 10-year median of 22.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (BSP:V2EE34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$47.45, compared to a current price of R$30.58 — trading 35.6% below its estimated fair value. The current Altman Z-Score is 12.14, which is 47% below median its 10-year median of 22.98 and 403.7% above the Healthcare Providers & Services industry median of 2.41. Veeva Systems' overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Veeva Systems (BSP:V2EE34), the current Altman Z-Score is 12.14 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (BSP:V2EE34) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of R$30.58 is trading 35.6% below its estimated GF Value™ of R$47.45.
GuruFocus considers Veeva Systems to be Significantly Undervalued.
Key valuation signals for BSP:V2EE34:
Altman Z-Score: 12.14 (47% below median its 10-year median of 22.98)
GF Value™: R$47.45 vs. price of R$30.58 (35.6% below fair value)
Industry Position: 403.7% above the Healthcare Providers & Services median (#49 of 659)
No single metric tells the full story. See the BSP:V2EE34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
97GF Score
Get the complete analysis for BSP:V2EE34
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:V2EE34 has been successfully added to your 
